Antibody drug conjugates are novel agents developed for the treatment of a variety of cancers, including lung cancer. This webinar describes the mechanism of action of these agents and will inform the audience of the current use and areas of development. Since these agents are very novel, it is important to discuss the unique side effects associated with treatment and the management of these unique toxicities. Brought to you by IASLC’s Education Committee.

Live Activity Date: August 23, 2023
Enduring Activity Launch Date: December 19, 2023
Enduring Activity Expiration Date: December 18, 2024

Physicians, nurses, allied health professionals, and researchers.

Upon completion of this activity, the participants should be able to: 

• Describe and understand the mechanism of action of ADC.
• Identify drugs in development and indications.
• Differentiate drug related adverse events and management of side effects.

Moderator:

• Antoinette Wozniak, MD, Lung Cancer Research Foundation, University of Pittsburgh

Presenters:

• Alona Zer, MD, Rambam Health Care Campus, Haifa, Israel
• Daniel Tan, MD, BSc, MBBS, MRCP, National Cancer Centre, Singapore
• Benjamin Levy, MD, Johns Hopkins University, School of Medicine

The following planners, speakers, reviewers, or staff have relevant financial relationships to disclose: 

Full Legal Name	Commercial Interest	Role	Level of Participation in the Activity
Antoinette Wozniak	EPIC Pharma	Speaker	Planner/Moderator
	OncLive/MJH Life Sciences	Speaker
	Daiichi-Sankyo	Consultant
Daniel Tan	AstraZeneca	Consultant/Research Funding	Planner/Speaker
	Pfizer	Research Funding
	ACM Biolabs	Research Funding
	Amgen	Consultant/Research Funding
	Pfizer	Consultant
	Novartis	Consultant
	Takeda	Consultant
	Bayer	Consultant
	DKSH Indonesia	Consultant
	Roche	Consultant
	GSK	Consultant
	C2i Genomics	Stock/Stock Options
	AIMIL Pharmaceuticals	Stock/Stock Options
	Oncoshot	Stock/Stock Options
Benjamin Levy	AstraZeneca	Consultant	Planner/Speaker
	Daiichi Sankyo	Consultant
	Janssen Pharmaceuticals	Consultant
	Eli Lilly	Consultant
	Merck	Consultant
	Genentech/Roche	Consultant
	Novartis	Consultant
	Amgen	Consultant
	Takeda Pharmaceuticals	Consultant
	Pfizer	Consultant
Alona Zer	AstraZeneca	Advisor	Planner/Speaker
	Roche	Research Funding
	MSD	Research Funding
	XAIR/Beyond Air	Consultant
	Takeda Pharmaceuticals	Advisor

"I have at present or have had within the last 24 months, a financial relationship with one or more ineligible companies."

These relationships with ineligible companies have been mitigated by the International Association for the Stufy of Lung Cancer (IASLC). 

All other presenters, planners, editors, or staff report no relationshops to disclose:

"I do not have at present nor have had within the last 24 months, any financial relationships with ineligible companies."

Accreditation Statement: 
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME). The International Association for the Study of Lung Cancer is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statements:

Physicians
The International Association for the Study of Lung Cancer designates the enduring activity for a maximum of 1.00 AMA PRA Category 1 Credits^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Nurse Practitioners and Registered Nurses
For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education).

Physician Assistants
The National Commission on Certification of Physician Assistants (NCCPA) states that the AMA PRA Category 1 Credits™ are acceptable for continuing medical education requirements for recertification.

International CPD Credit Reciprocity Agreements

Canada
The Royal College will recognize the number of participation hours as MOC Program Section 1 accredited group learning credits for group learning activities developed by Accreditation Council for Continuing Medical Education (ACCME)-accredited physician organizations (university, academy, specialty society, hospital department etc.) that are held within and outside of Canada. Agreement dates: November 1, 2019 to December 31, 2025.

European Union
The European Union of Medical Specialists (UEMS)-European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).

Qatar
The American Medical Association (AMA) and the Department of Healthcare Professions–Accreditation Section (DHP-AS), Ministry of Public Health–Qatar have renewed their CME agreement under which select activities approved for AMA PRA Category 1 Credit™ are eligible for conversion of the hours of participation to Department of Healthcare Professions Continuing Professional Development (DHP-CPD) credit. This agreement is in place through Dec. 31, 2026.

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; participants should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

1. Read about the target audience, learning objectives, and author disclosures.
2. Study the educational content online or print it out, if applicable.
3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test.
4. Complete the activity evaluation to provide feedback for future programming and receive credit.

You may now view or print the certificate from your CME/CE Transcript. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Transcript and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Transcript.

*The credit that you receive is based on your membership profile.

If you need assistance with this activity, please email: education@iaslc.org.